Pfizer (PFE) Tops Q1 EPS by 29c, Beats on Revenue; Offers FY24 Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Pfizer stock climbs as first quarter earnings, revenue come ahead of estimates
May 1, 2024 6:53 AM EDTPfizer (NYSE: PFE) shares rose 3% in premarket trading Wednesday after the drugmaker reported Q1 earnings and revenue that beat analyst estimates.
Earnings per share (EPS) stood at $0.82, exceeding the consensus estimates of $0.53. Revenue came in at $14.9 billion, also above the consensus projection of $14.04 billion.
Meanwhile, adjusted research and development (R&D) expenses... More
